Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Trevi Therapeutics (TRVI) Financials

Trevi Therapeutics logo
$14.18 +0.31 (+2.20%)
As of 03:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Trevi Therapeutics

Annual Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -27 -33 -34 -29 -29 -48 -43
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48 -43
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48 -43
Total Pre-Tax Income 		-21 -26 -33 -34 -29 -29 -48 -43
Total Operating Income		 -18 -27 -32 -32 -30 -34 -52 -49
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 27 32 32 30 34 52 49
Selling, General & Admin Expense		 4.34 7.31 10 9.49 10 10 12 16
Research & Development Expense		 14 19 22 23 20 24 39 33
Total Other Income / (Expense), net		 -2.26 0.58 -0.29 -1.49 0.72 4.83 3.58 6.51
Interest Expense		 0.17 0.00 0.46 1.20 1.16 0.39 0.00 0.00
Interest & Investment Income		 0.16 0.79 0.18 0.01 1.74 4.75 3.60 6.54
Other Income / (Expense), net		 -2.24 -0.22 -0.01 -0.29 0.14 0.47 -0.02 -0.03
Income Tax Expense		 -0.12 -0.02 -0.02 -0.02 -0.04 -0.03 -0.03 -0.06
Basic Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Weighted Average Basic Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M 134.75M
Diluted Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Weighted Average Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M 134.75M
Weighted Average Basic & Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M 128.40M

Quarterly Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.67 -7.85 -11 -12 -13 -12 -10 -12 -12 -8.32 -13
Consolidated Net Income / (Loss)		 -7.70 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13
Net Income / (Loss) Continuing Operations		 -7.70 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13
Total Pre-Tax Income 		-7.71 -7.80 -11 -12 -13 -11 -10 -12 -12 -8.33 -13
Total Operating Income		 -9.05 -8.93 -12 -13 -14 -12 -11 -14 -14 -10 -15
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.05 8.93 12 13 14 12 11 14 14 10 15
Selling, General & Admin Expense		 2.72 2.42 3.10 3.27 2.86 2.91 3.66 4.33 3.83 4.03 4.97
Research & Development Expense		 6.32 6.52 8.80 10 11 9.33 7.81 9.39 10 6.19 9.94
Total Other Income / (Expense), net		 1.33 1.13 1.00 0.93 0.81 0.84 1.12 1.40 2.10 1.89 1.70
Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Interest & Investment Income		 1.18 1.14 1.00 0.94 0.83 0.84 1.13 1.41 2.10 1.90 1.70
Other Income / (Expense), net		 0.15 -0.00 -0.00 -0.01 -0.01 0.00 -0.01 -0.01 -0.00 -0.02 0.00
Income Tax Expense		 -0.01 0.02 -0.01 -0.01 -0.03 0.02 -0.01 -0.02 -0.02 -0.02 -0.02
Basic Earnings per Share		 ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09)
Weighted Average Basic Shares Outstanding		 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M
Diluted Earnings per Share		 ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09)
Weighted Average Diluted Shares Outstanding		 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M
Weighted Average Basic & Diluted Shares Outstanding		 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M 121.78M 128.23M 128.40M 141.98M

Annual Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -15 50 -12 -8.17 -24 20 1.70 -15
Net Cash From Operating Activities		 -18 -23 -29 -29 -28 -32 -38 -42
Net Cash From Continuing Operating Activities		 -18 -23 -29 -29 -28 -32 -38 -42
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48 -43
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48 -43
Depreciation Expense		 0.02 0.04 0.05 0.05 0.04 0.12 0.15 0.14
Amortization Expense		 0.06 0.00 0.23 0.60 -0.31 -1.95 -1.37 -1.64
Non-Cash Adjustments To Reconcile Net Income		 2.77 0.97 2.43 2.84 2.47 3.02 4.05 5.66
Changes in Operating Assets and Liabilities, net		 -0.64 1.95 1.06 1.51 -1.23 -3.85 6.83 -3.49
Net Cash From Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22 -94
Net Cash From Continuing Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22 -94
Purchase of Property, Plant & Equipment		 -0.16 -0.01 -0.03 0.00 -0.16 -0.14 -0.04 -0.01
Purchase of Investments		 - - - 0.00 -126 -9.93 -98 -171
Sale and/or Maturity of Investments		 - - - 0.00 19 69 77 77
Net Cash From Financing Activities		 3.63 73 17 21 111 -7.91 61 121
Net Cash From Continuing Financing Activities		 3.63 73 17 21 111 -7.91 61 121
Repurchase of Common Equity		 -1.53 -1.21 -0.38 -0.38 -0.23 -0.26 0.00 -0.81
Issuance of Common Equity		 0.00 65 0.01 14 105 0.07 0.07 0.12
Other Financing Activities, net		 -0.52 -0.64 3.17 7.51 12 1.69 61 122
Cash Interest Paid		 0.15 0.00 0.18 0.60 0.59 0.33 0.00 0.00

Quarterly Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 6.43 -19 -0.85 3.09 18 -15 98 -60 -38 0.50
Net Cash From Operating Activities		 -7.28 -6.36 -10 -8.68 -9.56 -9.55 -13 -10 -11 -7.63 -17
Net Cash From Continuing Operating Activities		 -7.28 -6.36 -10 -8.68 -9.56 -9.55 -13 -9.99 -11 -7.63 -17
Net Income / (Loss) Continuing Operations		 -7.70 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13
Consolidated Net Income / (Loss)		 -7.70 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13
Depreciation Expense		 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03
Amortization Expense		 -0.61 -0.35 -0.38 -0.34 -0.35 -0.30 -0.40 -0.38 -0.30 -0.56 -0.43
Non-Cash Adjustments To Reconcile Net Income		 0.79 1.04 0.84 1.24 0.85 1.12 1.32 1.61 1.35 1.49 2.30
Changes in Operating Assets and Liabilities, net		 0.21 0.74 -0.06 2.73 3.15 1.01 -4.10 1.05 -0.17 -0.27 -5.40
Net Cash From Investing Activities		 18 13 -8.09 2.77 7.67 -24 -9.95 -2.61 -51 -31 17
Net Cash From Continuing Investing Activities		 18 13 -8.09 2.77 7.67 -24 -9.95 -2.61 -51 -31 17
Purchase of Property, Plant & Equipment		 -0.02 -0.02 - -0.03 - -0.01 0.00 - -0.01 - -0.10
Purchase of Investments		 - -0.95 -30 -9.96 -13 -45 -28 -17 -72 -54 -8.49
Sale and/or Maturity of Investments		 18 14 22 13 21 21 18 15 21 24 26
Net Cash From Financing Activities		 1.51 -0.05 -0.03 5.07 4.98 51 8.71 110 1.63 0.28 0.22
Net Cash From Continuing Financing Activities		 1.51 -0.05 -0.03 5.07 4.98 51 8.71 110 1.63 0.28 0.22
Repurchase of Common Equity		 -0.17 -0.06 0.00 - - - -0.22 -0.37 -0.22 - 0.00
Other Financing Activities, net		 1.68 -0.03 -0.03 5.03 4.98 51 8.93 2.55 1.85 108 0.22

Annual Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 60 47 38 123 89 111 193
Total Current Assets		 8.82 60 46 38 123 88 109 192
Cash & Equivalents		 7.20 57 45 37 13 32 34 19
Short-Term Investments		 - - - 0.00 108 51 74 169
Prepaid Expenses		 1.44 1.68 1.00 0.89 0.80 3.62 0.94 1.26
Other Current Assets		 0.18 0.56 0.27 0.24 1.31 0.96 0.87 2.13
Plant, Property, & Equipment, net		 0.15 0.12 0.10 0.05 0.17 0.22 0.16 0.18
Total Noncurrent Assets		 1.55 0.33 0.76 0.47 0.23 1.64 1.32 1.61
Noncurrent Note & Lease Receivables		 - - - - 0.00 0.21 0.16 0.00
Other Noncurrent Operating Assets		 1.55 0.33 0.76 0.47 0.23 1.43 1.16 1.61
Total Liabilities & Shareholders' Equity		 11 60 47 38 123 89 111 193
Total Liabilities		 4.28 5.46 20 21 16 6.86 11 10
Total Current Liabilities		 2.68 5.20 5.56 13 13 5.82 11 9.75
Accounts Payable		 0.60 1.60 2.02 2.85 2.86 1.81 3.41 3.91
Accrued Expenses		 2.07 3.50 3.43 3.81 3.52 3.71 6.81 5.53
Other Current Liabilities		 0.00 0.10 0.11 0.23 0.03 0.31 0.29 0.31
Total Noncurrent Liabilities		 1.60 0.26 14 8.68 2.16 1.03 0.75 0.45
Long-Term Debt		 - 0.00 14 8.65 2.15 0.00 - 0.00
Other Noncurrent Operating Liabilities		 1.56 0.00 0.20 0.00 0.00 0.03 0.75 0.45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 55 27 17 107 83 100 183
Total Preferred & Common Equity		 -109 55 27 17 107 83 100 183
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -109 55 27 17 107 83 100 183
Common Stock		 0.00 169 174 198 318 322 387 513
Retained Earnings		 -109 -114 -147 -181 -210 -239 -287 -330
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.12 -0.03 0.06 0.15

Quarterly Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 128 116 101 96 79 74 69 107 208 199 180
Total Current Assets		 127 114 99 94 77 72 67 106 207 198 176
Cash & Equivalents		 67 12 14 26 14 13 16 19 117 57 19
Short-Term Investments		 59 100 80 63 59 57 49 84 87 138 152
Prepaid Expenses		 1.29 1.33 2.98 4.04 3.23 1.80 1.18 1.53 1.77 1.38 2.22
Other Current Assets		 0.42 1.61 2.08 1.05 0.72 0.83 0.67 0.83 1.58 2.00 2.12
Plant, Property, & Equipment, net		 0.07 0.25 0.23 0.24 0.20 0.20 0.17 0.28 0.24 0.21 0.27
Total Noncurrent Assets		 0.92 1.76 1.54 1.71 1.59 1.48 1.40 1.11 0.87 0.84 3.22
Noncurrent Note & Lease Receivables		 - 0.24 0.23 0.22 0.19 0.18 0.17 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 0.92 1.52 1.31 1.49 1.40 1.30 1.23 1.11 0.87 0.84 3.22
Total Liabilities & Shareholders' Equity		 128 116 101 96 79 74 69 107 208 199 180
Total Liabilities		 18 14 5.90 6.29 6.23 7.64 9.94 7.55 9.85 9.57 7.48
Total Current Liabilities		 15 13 4.71 5.17 5.28 6.75 9.12 6.87 9.24 9.04 7.12
Accounts Payable		 2.33 1.98 1.35 1.26 2.11 1.51 1.61 1.42 2.97 2.71 2.22
Accrued Expenses		 5.25 3.47 3.08 3.63 2.84 4.93 7.21 5.17 5.98 6.04 4.58
Other Current Liabilities		 0.06 0.26 0.28 0.29 0.32 0.31 0.30 0.28 0.29 0.30 0.32
Total Noncurrent Liabilities		 3.82 1.27 1.19 1.11 0.95 0.88 0.82 0.68 0.61 0.53 0.36
Long-Term Debt		 3.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.02 0.12 0.09 0.06 0.00 0.00 0.00 0.68 0.61 0.53 0.36
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 110 102 95 90 72 66 59 99 198 190 172
Total Preferred & Common Equity		 110 102 95 90 72 66 59 99 198 190 172
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 110 102 95 90 72 66 59 99 198 190 172
Common Stock		 315 318 319 321 322 329 334 397 508 511 515
Retained Earnings		 -205 -216 -224 -231 -250 -262 -276 -297 -310 -321 -343
Accumulated Other Comprehensive Income / (Loss)		 -0.26 -0.09 -0.25 -0.22 -0.07 -0.08 0.14 0.07 0.02 0.03 -0.19

Annual Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - 128,230,134.00
DEI Adjusted Shares Outstanding		 - - - - - - - 128,230,134.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.33
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36 -35
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -28.42% -35.93% -18.84%
Earnings before Interest and Taxes (EBIT)		 -21 -27 -32 -33 -30 -33 -52 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -27 -32 -32 -30 -35 -53 -51
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 -22 -21 -22 -28 -28 -37
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.91 -2.51 -3.62 -5.25 -3.90 0.58 -7.23 -5.02
Increase / (Decrease) in Invested Capital		 0.00 -1.60 -1.11 -1.63 1.35 4.48 -7.81 2.96
Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30 $1.43
Tangible Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30 $1.43
Total Capital		 6.29 55 41 32 117 84 100 183
Total Debt		 0.05 0.26 14 15 9.15 1.00 0.75 0.00
Total Long-Term Debt		 0.05 0.26 14 8.68 2.15 1.00 0.75 0.00
Net Debt		 -7.16 -57 -31 -22 -111 -82 -107 -188
Capital Expenditures (CapEx)		 0.16 0.01 0.03 0.00 0.16 0.14 0.04 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.05 -2.96 -4.29 -5.76 -4.29 -1.25 -8.70 -6.35
Debt-free Net Working Capital (DFNWC)		 6.15 54 41 31 116 82 99 182
Net Working Capital (NWC)		 6.15 54 41 25 109 82 99 182
Net Nonoperating Expense (NNE)		 7.66 7.40 10 11 8.22 5.32 12 8.23
Net Nonoperating Obligations (NNO)		 -7.16 -57 -31 -22 -111 -82 -107 -188
Total Depreciation and Amortization (D&A)		 0.08 0.04 0.27 0.65 -0.27 -1.82 -1.22 -1.49
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M 134.75M
Adjusted Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M 134.75M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M 128.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36 -35
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 128,230,134.00 128,397,271.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 128,230,134.00 128,397,271.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.06 -0.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -11.78% -35.80% -53.76% -58.29% -52.25% -35.10% 3.42% -3.55% 1.64% - -29.33%
EBIT Growth		 -5.78% -40.33% -60.95% -61.55% -58.56% -36.97% 3.62% -3.27% 1.28% - -29.91%
NOPAT Growth		 -7.61% -34.19% -57.42% -58.54% -55.74% -37.04% 3.66% -3.26% 1.21% - -30.01%
Net Income Growth		 6.87% -42.07% -70.32% -72.88% -72.02% -45.95% 5.16% 0.41% 10.87% - -27.58%
EPS Growth		 33.33% -260.00% -83.33% -71.43% -62.50% -37.50% 18.18% 25.00% 38.46% - 0.00%
Operating Cash Flow Growth		 15.12% -0.44% -27.69% 12.07% -31.28% -50.18% -28.76% -16.33% -13.86% - -23.83%
Free Cash Flow Firm Growth		 -183.54% -78.57% -7.80% 64.89% 81.88% 92.90% 61.15% -37.28% -336.89% - -287.21%
Invested Capital Growth		 136.59% 114.80% 151.67% -220.58% -418.35% -1,353.21% -920.73% -121.26% 9.97% - 109.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -10.26% 2.28% -32.44% -10.93% -6.06% 13.29% 5.32% -18.93% -0.74% - -42.15%
EBIT Q/Q Growth		 -8.04% -0.51% -33.25% -11.65% -6.05% 13.18% 6.24% -19.63% -1.38% - -45.64%
NOPAT Q/Q Growth		 -7.91% 1.24% -33.28% -11.62% -6.01% 13.10% 6.31% -19.63% -1.41% - -45.91%
Net Income Q/Q Growth		 -7.74% -1.60% -39.39% -13.30% -7.21% 13.80% 9.42% -18.97% 4.06% - -58.63%
EPS Q/Q Growth		 -14.29% 0.00% -37.50% -9.09% -8.33% 15.38% 18.18% 0.00% 11.11% - -50.00%
Operating Cash Flow Q/Q Growth		 26.29% 12.64% -64.60% 17.04% -10.05% 0.06% -41.12% 25.05% -7.71% - -118.70%
Free Cash Flow Firm Q/Q Growth		 5.60% 17.63% 9.65% 50.02% 51.29% 67.74% -394.62% -76.59% -55.03% - -44.15%
Invested Capital Q/Q Growth		 -11.28% -67.82% -19.76% -626.35% -134.22% -26.68% 47.45% -41.89% 4.69% - 106.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 99.83% 100.23% 99.93% 99.94% 99.77% 100.15% 99.89% 99.83% 99.87% - 99.85%
Interest Burden Percent		 86.73% 87.32% 91.63% 92.97% 94.15% 93.12% 90.20% 89.75% 84.90% - 88.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -26.81% -30.59% -38.57% -48.09% -59.65% -52.59% -55.12% -35.74% -36.87% - -33.59%
Cash Return on Invested Capital (CROIC)		 -1,608.81% -4,891.01% -6,078.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -11,942.73%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -26.81% -30.59% -38.57% -48.09% -59.65% -52.59% -55.12% -35.74% -36.87% - -33.59%
Return on Equity Simple (ROE_SIMPLE)		 -29.85% 0.00% -46.40% -58.59% -75.15% 0.00% -47.61% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03 -9.61 -9.74 -7.15 -10
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.35% -1.62% -2.94% -3.77% -4.43% -3.01% -2.64% -1.98% -1.59% - -2.00%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.48% - - - -8.54% -8.07% -4.84% -5.13% -3.90% -6.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.89 -8.94 -12 -13 -14 -12 -11 -14 -14 -10 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.47 -9.25 -12 -14 -14 -12 -12 -14 -14 -11 -15
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.55 1.04 3.29 3.17 4.11 3.18 6.11 2.80 5.87 - 8.90
Price to Tangible Book Value (P/TBV)		 1.55 1.04 3.29 3.17 4.11 3.18 6.11 2.80 5.87 - 8.90
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 28.65 6.24 358.62 0.00 0.00 0.00 0.00 0.00 0.00 - 3,953.48
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.02 -1.02 -1.00 -1.00 -1.03 -1.04 -1.02 -1.03 -1.04 - -1.01
Leverage Ratio		 1.12 1.12 1.12 1.08 1.11 1.10 1.08 1.07 1.08 - 1.06
Compound Leverage Factor		 0.97 0.98 1.03 1.01 1.04 1.02 0.97 0.96 0.92 - 0.94
Debt to Total Capital		 1.16% 1.20% 1.30% 1.32% 1.36% 0.74% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 1.16% 1.20% 1.30% 1.32% 1.36% 0.74% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 98.84% 98.80% 98.71% 98.68% 98.64% 99.26% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 2.67 2.32 1.82 1.54 1.31 2.03 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 3.96 3.45 2.68 2.27 1.92 2.96 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02 0.00 0.00 0.00 - 0.00
Altman Z-Score		 10.71 4.51 19.07 11.98 9.38 13.96 45.21 32.76 68.53 - 121.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.16 15.03 14.55 10.68 7.38 10.41 15.38 22.42 21.93 - 24.75
Quick Ratio		 17.18 14.25 13.80 10.29 7.18 10.24 15.04 22.06 21.56 - 24.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -11 -9.69 -4.84 -2.36 -0.76 -3.77 -6.65 -10 -10 -15
Operating Cash Flow to CapEx		 -40,438.89% -28,904.55% 0.00% -31,010.71% 0.00% -136,428.57% 0.00% 0.00% -90,666.67% - -16,361.76%
Free Cash Flow to Firm to Interest Expense		 -4,341.50 -2,682.03 -9,693.20 -4,844.30 -2,359.90 -761.40 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 -2,426.33 -1,589.75 -10,467.00 -8,683.00 -9,556.00 -9,550.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2,432.33 -1,595.25 -10,467.00 -8,711.00 -9,556.00 -9,557.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.79 0.58 0.46 -2.44 -5.71 -7.23 -3.80 -5.39 -5.14 -5.02 0.34
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 6.69 4.48 1.36 -4.46 -7.50 -7.81 -4.26 -2.96 0.57 2.96 4.14
Enterprise Value (EV)		 51 3.60 166 141 178 210 505 353 919 - 1,360
Market Capitalization		 139 86 238 210 242 317 608 557 1,114 - 1,532
Book Value per Share		 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03 $1.95 $1.56 $1.43 $1.34
Tangible Book Value per Share		 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03 $1.95 $1.56 $1.43 $1.34
Total Capital		 91 84 73 67 60 100 99 198 190 183 172
Total Debt		 1.05 1.00 0.95 0.88 0.82 0.75 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.05 1.00 0.95 0.88 0.82 0.75 0.00 0.00 0.00 0.00 0.00
Net Debt		 -88 -82 -72 -69 -65 -107 -103 -204 -195 -188 -172
Capital Expenditures (CapEx)		 0.02 0.02 0.00 0.03 0.00 0.01 0.00 0.00 0.01 0.00 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.09 -1.25 -1.33 -4.12 -7.28 -8.70 -4.50 -5.90 -5.67 -6.35 -2.78
Debt-free Net Working Capital (DFNWC)		 89 82 71 65 58 99 99 198 189 182 169
Net Working Capital (NWC)		 89 82 71 65 58 99 99 198 189 182 169
Net Nonoperating Expense (NNE)		 1.37 1.57 2.57 3.05 3.38 2.85 2.31 2.70 2.06 1.16 2.75
Net Nonoperating Obligations (NNO)		 -88 -82 -72 -69 -65 -107 -103 -204 -195 -188 -172
Total Depreciation and Amortization (D&A)		 -0.58 -0.32 -0.35 -0.30 -0.32 -0.26 -0.36 -0.35 -0.26 -0.53 -0.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M
Adjusted Diluted Earnings per Share		 ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M 121.78M 128.23M 128.40M 141.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03 -9.61 -9.74 -7.15 -10
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,963.67 -2,234.00 -11,907.00 -13,294.00 -14,098.00 -12,240.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 -2,110.50 -1,563.28 -8,334.20 -9,302.30 -9,860.90 -8,569.40 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 -2,969.67 -2,239.50 -11,907.00 -13,322.00 -14,098.00 -12,247.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 -2,116.50 -1,568.78 -8,334.20 -9,330.30 -9,860.90 -8,576.40 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -0.86% -0.89% -0.72% -0.59% -0.13% 0.00% -0.47% -1.25% -1.76% - -1.29%

Financials Breakdown Chart

Key Financial Trends

Trevi Therapeutics (TRVI) has faced ongoing losses, but it also shows a strong liquidity base and active financing activity that has helped fund operations. Below are the key takeaways from the last several years of quarterly data, focused on the income statement, cash flow, and balance sheet metrics.

  • Strong liquidity and low near-term liabilities as of Q3 2025: Cash & Equivalents about $56.9M and Short-Term Investments about $138.1M (total roughly $195M in liquid assets), Total Current Assets about $198.3M, and Total Current Liabilities around $9.04M. The company also shows no long-term debt, with Total Assets near $199.36M and Total Equity around $189.79M.
  • No long-term debt observed: Long-Term Debt is 0.0 across the latest balance sheets (e.g., Q3 2025), reducing leverage risk relative to many biotech peers.
  • Financing activity provides runway: Net cash from financing activities has been positive in several quarters, reflecting equity-based funding (issuances of common equity and other financing activity) that supports liquidity without added debt.
  • Improved quarterly performance in latest quarter: In Q4 2025, Net Income Attributable to Common Shareholders was -$8.316M and Basic/Diluted EPS stood at -$0.06, an improvement versus Q3 2025 (Net Income -$11.802M; EPS around -$0.08), signaling a narrowing loss in the most recent period.
  • Revenue has been effectively zero in the covered periods: Total Revenue is reported as 0 in several quarters, indicating the company remains pre-revenue and focused on development activities rather than product sales.
  • Shares outstanding and EPS context: Weighted average shares outstanding have been in the low-to-mid hundreds of millions across periods (examples include ~128–146 million for various measures), contributing to negative EPS when losses occur. This is typical of a development-stage biotech moving toward potential future milestones.
  • Equity base remains sizable: Total Common Equity around $99M to $190M across quarters (e.g., about $189.8M in Q3 2025), indicating substantial paid-in capital and accumulated losses have not eroded total equity.
  • Operating cash flow remains negative: Net cash from continuing operating activities is negative in all observed quarters (e.g., -$7.63M in Q4 2025 and -$10.88M in Q3 2025), signaling ongoing cash burn absent revenue generation.
  • Investing cash outflows are substantial: Significant cash outlays for purchasing investments (e.g., Q3 2025 around -$71.6M; Q4 2025 around -$54.4M; Q2 2025 around -$17.1M in some periods), contributing to negative cash flow from investing activities and pressuring liquidity in some quarters.
  • Persistent net losses and accumulated deficit: Net income from continuing operations is negative across quarters (e.g., Q4 2025 -$8.316M; Q3 2025 -$11.802M; Q2 2025 -$12.301M; Q1 2025 -$10.343M). Retained Earnings are significantly negative (e.g., -$321.488M in Q3 2025), underscoring a substantial accumulated deficit that must be addressed for long-run profitability.
05/21/26 02:57 PM ETAI Generated. May Contain Errors.

Trevi Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Trevi Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Trevi Therapeutics' net income appears to be on an upward trend, with a most recent value of -$42.76 million in 2025, rising from -$20.55 million in 2018. The previous period was -$47.91 million in 2024. Check out Trevi Therapeutics' forecast to explore projected trends and price targets.

Trevi Therapeutics' total operating income in 2025 was -$49.33 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $49.33 million

Over the last 7 years, Trevi Therapeutics' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Trevi Therapeutics' total liabilities were at $10.20 million at the end of 2025, a 9.4% decrease from 2024, and a 138.3% increase since 2018.

In the past 7 years, Trevi Therapeutics' cash and equivalents has ranged from $7.20 million in 2018 to $57.31 million in 2019, and is currently $18.91 million as of their latest financial filing in 2025.

Over the last 7 years, Trevi Therapeutics' book value per share changed from -250.21 in 2018 to 1.43 in 2025, a change of -100.6%.


Related Companies

Financial statements for NASDAQ:TRVI last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel